SCHEMBL298092

SCHEMBL298092

CS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3nccc(Cl)c23)c1F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 12/20 0.73
CYP2C9 P11712 11/20 0.57
CYP2C19 P33261 5/20 0.54
BMPR1B O00238 1/20 0.52
PLK4 O00444 1/20 0.52
PIR O00625 1/20 0.52
AURKA O14965 1/20 0.52
DCLK1 O15075 1/20 0.52
EPHB6 O15197 1/20 0.52
RIPK2 O43353 1/20 0.52
STK16 O75716 1/20 0.52
OXSR1 O95747 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
RAF1 P04049 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
FES P07332 1/20 0.52
CSF1R P07333 1/20 0.52
YES1 P07947 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7875508 0.90 CYP3A4 (0.71) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL298557 0.89 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL298587 0.89 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL299436 0.88 BRAF (0.69) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL299419 0.87 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL298457 0.87 CYP3A4 (0.73) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL298894 0.87 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL298570 0.87 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19BMPR1BPLK4
SCHEMBL299360 0.86 CYP3A4 (0.83) CYP3A4CYP2C9CYP2C19
SCHEMBL293029 0.86 CYP3A4 (0.77) CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP3A4 3611/4885CYP2C9 2176/4885CYP2C19 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.